Roivant Sciences (ROIV) Competitors $11.78 +0.06 (+0.47%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ROIV vs. BNTX, INSM, TEVA, SMMT, GMAB, VTRS, ASND, RDY, QGEN, and MRNAShould you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BioNTech (BNTX), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Roivant Sciences vs. Its Competitors BioNTech Insmed Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN Moderna Roivant Sciences (NASDAQ:ROIV) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Does the media refer more to ROIV or BNTX? In the previous week, BioNTech had 14 more articles in the media than Roivant Sciences. MarketBeat recorded 21 mentions for BioNTech and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.62 beat BioNTech's score of 0.35 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioNTech 8 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Is ROIV or BNTX more profitable? BioNTech has a net margin of -12.20% compared to Roivant Sciences' net margin of -2,111.79%. BioNTech's return on equity of -1.84% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-2,111.79% -15.90% -14.95% BioNTech -12.20%-1.84%-1.59% Do insiders and institutionals hold more shares of ROIV or BNTX? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher valuation and earnings, ROIV or BNTX? Roivant Sciences has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$29.05M275.55-$171.98M-$0.70-16.82BioNTech$2.98B8.91-$719.92M-$1.60-69.00 Which has more risk & volatility, ROIV or BNTX? Roivant Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Do analysts prefer ROIV or BNTX? Roivant Sciences currently has a consensus target price of $16.50, indicating a potential upside of 40.13%. BioNTech has a consensus target price of $135.80, indicating a potential upside of 23.01%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Roivant Sciences is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.76 SummaryRoivant Sciences beats BioNTech on 9 of the 17 factors compared between the two stocks. Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROIV vs. The Competition Export to ExcelMetricRoivant SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.98B$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-16.7820.4630.4325.11Price / Sales275.55237.31392.2187.48Price / CashN/A42.3737.0358.50Price / Book1.667.959.016.20Net Income-$171.98M-$54.72M$3.26B$265.38M7 Day Performance0.21%1.56%1.00%-1.25%1 Month Performance2.57%5.71%4.19%-0.81%1 Year Performance-0.13%9.01%28.39%18.83% Roivant Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROIVRoivant Sciences3.2864 of 5 stars$11.78+0.5%$16.50+40.1%+2.1%$7.98B$29.05M-16.78860BNTXBioNTech1.6389 of 5 stars$112.55-0.9%$135.80+20.7%+25.7%$27.29B$2.98B-70.346,772Analyst RevisionINSMInsmed4.1155 of 5 stars$127.27-0.4%$129.57+1.8%+69.9%$27.01B$363.71M-22.291,271Trending NewsAnalyst ForecastInsider TradeTEVATeva Pharmaceutical Industries3.5644 of 5 stars$18.08+1.2%$24.71+36.7%-3.7%$20.48B$16.63B-113.0036,830Positive NewsSMMTSummit Therapeutics2.3809 of 5 stars$26.29-1.5%$35.00+33.1%+110.2%$19.83B$700K-26.03110News CoverageAnalyst ForecastGMABGenmab A/S3.8755 of 5 stars$23.42+0.5%$37.60+60.5%-11.5%$14.95B$3.12B11.772,682Positive NewsAnalyst DowngradeAnalyst RevisionVTRSViatris2.0063 of 5 stars$10.63+0.2%$10.40-2.2%-8.7%$12.37B$14.74B-3.6732,000ASNDAscendis Pharma A/S2.5085 of 5 stars$194.08-2.1%$242.93+25.2%+39.3%$12.13B$490.75M-37.611,017News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories3.043 of 5 stars$14.26+0.2%$16.95+18.9%-15.0%$11.87B$3.81B21.6027,811News CoverageGap UpQGENQIAGEN3.7612 of 5 stars$48.66-1.4%$49.69+2.1%+7.8%$10.97B$1.98B28.755,765MRNAModerna4.3827 of 5 stars$28.09+0.2%$43.59+55.2%-69.1%$10.90B$3.24B-3.735,800 Related Companies and Tools Related Companies BNTX Competitors INSM Competitors TEVA Competitors SMMT Competitors GMAB Competitors VTRS Competitors ASND Competitors RDY Competitors QGEN Competitors MRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ROIV) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access